Bicalutamide 150 mg: Practical prescribing in patients with early prostate cancer

被引：2

作者：

Anderson, J ^{[1
]}

机构：

[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England

来源：

BJU INTERNATIONAL | 2004年 / 94卷 / 06期

关键词：

D O I：

10.1111/j.1464-410X.2004.05066.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：758 / 759

页数：2

共 50 条

[41] Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression - Editorial comment
Crawford, ED
UROLOGY, 2001, 58 (02) : 150 - 151
[42] ADJUVANT MAXIMUM ANDROGEN BLOCKAGE COMPARED WITH BICALUTAMIDE 150MG IN PATIENTS WITH LOCALIZED HIGH-RISK PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
Chang, Kun
Qin, Xiao-jian
Ye, Ding-wei
JOURNAL OF UROLOGY, 2016, 195 (04): : E996 - E997
[43] Bicalutamide 150 mg for early non-metastatic prostate cancer in patients who would otherwise undergo watchful waiting: Latest results at a median 5.4 years' follow-up
Iversen, P
McLeod, DG
See, WA
Wirth, MP
Morris, T
Carroll, K
JOURNAL OF UROLOGY, 2004, 171 (04): : 280 - 280
[44] Adjuvant hormonal treatment - The Bicalutamide Early Prostate Cancer Program
Wirth, Manfred P.
Hakenberg, Oliver W.
Froehner, Michael
CONTROVERSIES IN THE TREATMENT OF PROSTATE CANCER, 2008, 41 : 39 - 48
[45] Adjuvant bicalutamide therapy improves prognosis in early prostate cancer
不详
RADIOLOGE, 2006, 46 (02): : 167 - 168
[46] Bicalutamide 150 mg in addition to standard care significantly improves prostate specific antigen progression-free survival in patients with early, non-metastatic prostate cancer: Median 5.4 years' follow-up
See, WA
Iversen, P
McLeod, DG
Wirth, MP
Carroll, K
Morris, T
Morris, CD
JOURNAL OF UROLOGY, 2004, 171 (04): : 280 - 281
[47] Is there a relationship between early changes in sex hormone profile and gynaecomastia induced by bicalutamide 150 mg?
不详
EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 227 - 227
[48] Bicalutamide with radiotherapy for prostate cancer
Brower, Vicki
LANCET ONCOLOGY, 2017, 18 (03): : E141 - E141
[49] Bicalutamide 150 mg in addition to standard care in patients with early, non-metastatic prostate cancer: Results from the SPCG-6 study at a median follow-up of 5.3 years
Iversen, P
JOURNAL OF UROLOGY, 2004, 171 (04): : 311 - 312
[50] Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
M Wirth
C Tyrrell
K Delaere
M Sánchez-Chapado
J Ramon
D M A Wallace
J Hetherington
F Pina
C Heyns
T Borchers
T Morris
J Armstrong
Prostate Cancer and Prostatic Diseases, 2005, 8 : 194 - 200

← 1 2 3 4 5 →